Evidence map›Paper›PMID 40267274›Full record

ArticleThe American journal of gastroenterology2025

Patient-Perceived Risk of Hepatocellular Carcinoma and Net Benefit of Surveillance: A Multicenter Survey Study.

Amit G Singal, Ju Dong Yang, Prasun K Jalal, Reena Salgia, Neil Mehta, Maarouf A Hoteit, Karissa Kao, Darine Daher, Karim Seif El Dahan, Perla Hernandez and 6 more

Abstract readMulticenter Study
In one paragraph

Article in The American journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Validation of Texas Hepatocellular Carcinoma Consortium Risk Index in the Hepatocellular Carcinoma Early Detection Strategy Study.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Amit G SingalDepartment of Internal Medicine, UT Southwestern Medical Center and Parkland Health, Dallas, Texas, USA.
Ju Dong YangDepartment of Internal Medicine, Cedars Sinai, Los Angeles, California, USA.
Prasun K JalalDepartment of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA.
Reena SalgiaDepartment of Internal Medicine, Henry Ford Health System, Detroit, Michigan, USA.
Neil MehtaDepartment of Internal Medicine, UC San Francisco, San Francisco, California, USA.ORCID 0000-0002-9476-468
Maarouf A HoteitDepartment of Internal Medicine, University of Pennsylvania, Philadelphia, Pennsylvania , USA.
Karissa KaoDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Darine DaherDepartment of Internal Medicine, UT Southwestern Medical Center and Parkland Health, Dallas, Texas, USA.ORCID 0000-0002-9977-1176
Karim Seif El DahanDepartment of Internal Medicine, UT Southwestern Medical Center and Parkland Health, Dallas, Texas, USA.ORCID 0000-0003-4268-4079
Perla HernandezDepartment of Internal Medicine, Cedars Sinai, Los Angeles, California, USA.
Anish NayakDepartment of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA.ORCID 0009-0000-2666-9632
Naomy KimDepartment of Internal Medicine, Cedars Sinai, Los Angeles, California, USA.ORCID 0009-0008-7747-514
Sarah PhamDepartment of Internal Medicine, UC San Francisco, San Francisco, California, USA.ORCID 0009-0004-7206-0237
Jamine GamezDepartment of Internal Medicine, UC San Francisco, San Francisco, California, USA.ORCID 0009-0008-0407-2905
Jonathan P TroostMichigan Institute for Clinical and Health Research, Michigan Medicine, Ann Arbor, Michigan, USA.
Neehar D ParikhDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.

Funding

Clinical Validation Center for Hepatocellular CarcinomaU01CA271887 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI FASIHA KANWAL, JORGE A MARRERO · 2022 to 2026
$4.7M
Precision Risk Stratification and Screening for HCC among Patients with Indeterminate Liver NodulesU01CA283935 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HOSHIDA, YUJIN, SINGAL, AMIT · 2023 to 2025
$3.9M
Trial of Statins for Chemoprevention in Hepatocellular CarcinomaR01CA255621 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T, HOSHIDA, YUJIN · 2021 to 2025
$3.6M
Reverse-engineering precision liver cancer chemopreventionR01CA233794 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HOSHIDA, YUJIN · 2019 to 2023
$3.5M
Harms of Hepatocellular Carcinoma Screening in Patients with CirrhosisR01CA212008 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI SINGAL, AMIT · 2017 to 2022
$3.2M
Multi-level Evaluation of Racial/ethnic Disparities in Liver Disease OutcomesR01CA256977 · NCI · BAYLOR COLLEGE OF MEDICINE · PI KANWAL, FASIHA, SINGAL, AMIT · 2021 to 2025
$3.0M
Epigallocatechin gallate for prevention of lethal cirrhosis complicationsR01CA282178 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Yujin Hoshida, Amit Singal · 2023 to 2026
$1.8M
Cancer Prevention and Research Institute of Texas RP200554NCI NIH HHS R01 CA212008NCI NIH HHS R01 CA233794NCI NIH HHS R01 CA255621NCI NIH HHS R01 CA256977NCI NIH HHS R01 CA282178NCI NIH HHS U01 CA271887NCI NIH HHS U01 CA283935
6 · The paper itself

Abstract

introductionHepatocellular carcinoma (HCC) surveillance is underused in clinical practice, and few contemporary data have assessed patients' perceptions of surveillance effectiveness and net benefit.

methodsWe conducted a survey study among adult patients with cirrhosis at 7 health systems in the United States. The survey was based on validated measures, when available, and assessed patient knowledge about HCC surveillance, attitudes regarding surveillance benefits and harms, perceived HCC risk, and trust in their doctors.

resultsRespondents (n = 665; median age 60; 46.5% female) were knowledgeable about HCC surveillance, with no significant differences across sociodemographic groups; however, approximately 1 in 5 patients had knowledge gaps about the need and benefit of surveillance. Over three fourths of patients believed that surveillance improves early HCC detection (80.3%) and survival (77.9%). While 74.0% of patients reported that doctors had discussed surveillance benefits, only 54.2% recalled a discussion about potential harms. Patients placed greater importance on surveillance benefits, but expressed harms should be measured when assessing the net benefit of surveillance programs. Based on a pictogram depicting current estimates for surveillance benefits and harms, 93.2% of patients chose to undergo surveillance, with no significant differences by race, perceived surveillance benefits, or fear of dying from HCC. Study limitations include response and nonresponse biases, which may result in an overestimation of reported surveillance benefits and patient acceptance. DISCUSSION: Most patients with cirrhosis followed at academic health systems have high knowledge about HCC surveillance, believe that it is beneficial, and express interest in undergoing surveillance after being counseled about the benefits and harms.

Indexed as

Carcinoma, HepatocellularEarly Detection of CancerHealth Knowledge, Attitudes, PracticeLiver CirrhosisLiver NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedPopulation SurveillanceRisk AssessmentSurveys and QuestionnairesUnited Statesearly detectionknowledgeliver cancerscreeningsurvey

Identifiers

PMID40267274
PMCPMC12316564

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.